RVRC
Revium Rx.$1.43 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $1.43
1 year
+175.0%
from $0.5200 · Oct 28
30 days
0.0%
from $1.43
52-week range
$0.5200–1.67
−14% from high · low Oct 28
Avg volume 20D
0
Sep 29 spike 0
Filing reports
2
analyzed by SecBot
SecBot read MIXED 2 reports · latest
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- TrendRANGE
1% below its 50-day average.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jun 1, 2026 SEC Apr 20, 2026 SEC
Revium Rx. announced the resignation of CFO Arie Gordashnikov effective May 27, 2026, with no reported disagreement…
8-K — Impact 2/10
Revium Rx appointed Amir Avraham as permanent CEO effective February 1, 2026, and Shlomi Schwartzblat as a director…
8-K — Impact 3/10
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
SecBot reports
2 filings · 0 bullish · 0 bearish · 2 neutral- NEUTRAL 8-KJun 1, 2026
Revium Rx. announced the resignation of CFO Arie Gordashnikov effective May 27, 2026, with no…
This is a routine CFO transition with an experienced replacement. Monitor for any strategic or financial changes in subsequent filings, but no immediate trading action warranted.
- NEUTRAL 8-KApr 20, 2026
Revium Rx appointed Amir Avraham as permanent CEO effective February 1, 2026, and Shlomi…
Monitor for future funding announcements as the $50,000 bonus is tied to raising $5M in equity investments within 18 months; watch for potential share dilution from the 1.9 million stock options…
All RVRC filing & press-release reports (2)
- 8-K reportJun 1, 2026
- 8-K reportApr 20, 2026